Anti-CD40L Therapy Prevents the Formation of Precursor Lesions to Gastric B-cell MALT Lymphoma in a Mouse Model
Le Ying,Phoebe Liu,Zhoujie Ding,Georgie Wray-McCann,Jack Emery,Nina Colon,Lena H. M. Le,Le Son Tran,Ping Xu,Liang Yu,Dana J. Philpott,Yugang Tu,Daryl M. Z. Cheah,Chee L. Cheng,Soon T. Lim,Choon K. Ong,Richard L. Ferrero
DOI: https://doi.org/10.1002/path.6053
2023-01-01
The Journal of Pathology
Abstract:Mucosa-associated lymphoid tissue (MALT) lymphoma is a B-cell tumour that develops over many decades in the stomachs of individuals with chronic Helicobacter pylori infection. We developed a new mouse model of human gastric MALT lymphoma in which mice with a myeloid-specific deletion of the innate immune molecule, Nlrc5, develop precursor B-cell lesions to MALT lymphoma at only 3 months post-Helicobacter infection versus 9-24 months in existing models. The gastric B-cell lesions in the Nlrc5 knockout mice had the histopathological features of the human disease, notably lymphoepithelial-like lesions, centrocyte-like cells, and were infiltrated by dendritic cells (DCs), macrophages, and T-cells (CD4(+), CD8(+) and Foxp3(+)). Mouse and human gastric tissues contained immune cells expressing immune checkpoint receptor programmed death 1 (PD-1) and its ligand PD-L1, indicating an immunosuppressive tissue microenvironment. We next determined whether CD40L, overexpressed in a range of B-cell malignancies, may be a potential drug target for the treatment of gastric MALT lymphoma. Importantly, we showed that the administration of anti-CD40L antibody either coincident with or after establishment of Helicobacter infection prevented gastric B-cell lesions in mice, when compared with the control antibody treatment. Mice administered the CD40L antibody also had significantly reduced numbers of gastric DCs, CD8(+) and Foxp3(+) T-cells, as well as decreased gastric expression of B-cell lymphoma genes. These findings validate the potential of CD40L as a therapeutic target in the treatment of human gastric B-cell MALT lymphoma. (c) 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.